Furthermore, this observation was phenocopied upon addition of FYN720, a PP2A activator used in the treatment of multiple sclerosis, providing mechanistic evidence for PP2A and SET involvement in ASPS, and highlighting the potential clinical utility of FYN720 for the treatment of ASPS patients. This evidence concerns the gene SET and alveolar soft part sarcoma.